The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The current understanding of heart risks from chemotherapy does not stop oncologists from giving chemotherapy for early breast cancer in those who need it.
Better drugs for preventing relapse are certainly welcome, when they are developed.
The AGENDA trial is designed to determine whether the addition of Gensense to DTIC can impprove outcomes for melanoma patients as compared with DTIC alone.
- Hycamtin represents the first approved second line drug treatment for small cell lung cancer. - The oral preparation will avoid the need for intravenous lines and allow considerable flexibility in treating this disease. - Hycamtin will allow maintenance therapy for those patient who are unable...
Pemetrexed, in combination with Cisplatin, represents an effective first line therapy for patients with NSCLC. However, there is little to distinguish the activity of this regimen from that of other commonly used doublets and its major advantage may result from a more favorable toxicity profile. ...
Alemtuzumab has received FDA approval for use in patients with previously untreated CLL. This approval is based on a comparison with Chlorambucil, an agent not commonly used for first line treatment in the United States. The toxicity profile of CAMPATH and the availability of other agents,...
Humax-EGFr is an antibody targeting the EGF receptor. Currently, Cetuximab, another EGFr antibody is approved for the treatment of patients with unresectable head and neck cancer. Humax-EGFr could have a role in this disease if its efficacy is greater than or its toxicity profile is...
At present, no biologic agents have been approved for the treatment of her-2 negative breast cancer. The addition of Avastin to chemotherapy for patients with stage IV breast cancer has the potential to improve progression free survival and improve quality of life. FDA approval of...